Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD

Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma Phthalazine PDE4 inhibitors. Part 3: The synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 Inhibitors: A Potential Treatment for Asthma Design, synthesis and in vitro PDE4 inhibition activity of certain quinazolinone derivatives for treatment of asthma The discovery of long-acting saligenin β2 adrenergic receptor agonists incorporating hydantoin or uracil rings